Armata reports Q4 2022 loss of $10.3M; positive phage trial data, $30M financing closed

Armata Pharmaceuticals, Inc.

R&D expenses $9.6M in Q4 2022, up from $4.8M in Q4 2021, driven by clinical trial investment.
Cash $14.9M at Dec 31, 2022; closed $30M convertible credit with Innoviva in Q4.
Positive topline results from SWARM-P.a. Phase 1b/2a for AP-PA02 in CF patients; advancing to Phase 2b.
First patient dosed in Phase 2 NCFB study for AP-PA02; AP-SA02 bacteremia study first cohort completed.
Loss from operations $(10.3)M vs $(6.0)M in Q4 2021; grant revenue $1.1M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Armata Pharmaceuticals, Inc. reported financial results for full fiscal year ended December 31, 2022.

Period: full fiscal year ended December 31, 2022
Result: reported results

Exact text from the filing

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Armata Pharmaceuticals, Inc. reported three months ended December 31, 2022 results: revenue approximately $1.1 million.

Period: three months ended December 31, 2022
Revenue: approximately $1.1 million
Result: reported results

Exact text from the filing

team is well-positioned for a successful 2023,” concluded Dr. Varnum. Fourth Quarter 2022 Financial Results Grant Revenue. The Company recognized grant revenue of approximately $1.1 million for the three months ended December 31, 2022, which represents Medical Technology Enterprise Consortium (“MTEC”)’s share of the costs incurred for the Company’s AP-SA02 program

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Armata Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-004017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.